AONM WEBINAR SERIES

.jpg

Chris Woollams MA (Oxon, Biochemistry)

The Benefits of Complementary and Integrative Medicine in the Field of Oncology

The Effect of Natural Therapies and CTC (Circulating Cancer Cells) Testing on Patients with Cancer

Dr. Joseph Jemsek

Questions and Answer Session: Lyme Borreliosis complex and COVID-19. How do they interact?

Dr. Sarah Myhill

Questions and Answer Session: Interconnections between M.E. and COVID, and effective therapies. Following on from the earlier webinar in this series

Dr. Robert Bransfield

Questions and answers following the earlier “Tale of Two Pandemics: Lyme Disease and COVID-19” webinar

Dr. Armin Schwarzbach

SARS-CoV-2 Testing Part 2

Dr. Jodie Dashore

Interconnections between COVID-19, PANS/PANDAS and biotoxin illness

Dr. Robert C. Bransfield

PDF of presentation

A Tale of Two Pandemics Lyme Disease and COVID-19

Dr. Joseph Jemsek

Lyme Borreliosis Complex and COVID-19. How Do They Interact?

International Awareness Day Special 2020

Drs. Gilbert and Schwarzbach

SARS-CoV-2 (COVID-19) Testing Part 2: Introducing the First Multiplex ELISA to Incorporate Three Immunoglobulins

Jenna Luche-Thayer

Jenna Luché-Thayer on What are the Human Rights Challenges Around COVID-19

Dr. Judy Mikovits

Dr. Judy Mikovits talks about COVID-19

Dr. Armin Schwarzbach

Dr. Armin Schwarzbach on his research and approach to COVID-19 testing

Dr. Armin Schwarzbach

PDF presentation of the Webinar

Dr. Schwarzbach's presentation

The Association Between Hypercoagulation, MCAS, and Infections

Dr. Schwarzbach discusses the important and underrecognised links between infections and hypercoagulation (“sticky blood”), mast cell overreactivity (mast cell activation syndrome is one name for this – MCAS). Dr. Schwarzbach specialises in testing for tick-borne infections, but he will also be covering a wider range of pathogens, including viruses.

Dr. Katherina Pachmann

PDF presentation of the Webinar

Dr. Pachmann's presentation

Personalised Testing of Natural Substances in Order to Support Cancer Cell Apoptosis

Prof. Dr. Med. Katharina Pachmann discusses the methods that her laboratory uses, and their findings.

PROF. DR. MED. KATHARINA PACHMANN is the founder of the Maintrac system of identifying circulating cancer cells in a “liquid biopsy”, and runs the Maintrac laboratory in Bayreuth, Germany, together with Dr. Ulrich Pachmann and a staff of 45. As both a medical doctor and research scientist, she has been conducting studies in this field and refining related techniques for over two decades, and has authored over a hundred scientific publications on the technique (https://aonm.org/scientific-articles-and-studies/)

She received her PhD from the Institute for Haematology at the Society for Radiological Research, Munich, and worked as the Head of the Department of Experimental Haematology and Oncology, Friedrich Schiller-University, Jena, for many years. She is a visiting scientist at the University Clinic, Graz, Austria, and has also served in the same capacity at MD Anderson Cancer Center Houston Texas Section of Molecular Hematology and Therapy.

Dr. Craig D. Shimasaki

PDF presentation of the Webinar

Dr. Shimasaki's presentation

PANDAS/PANS and Other Infection-Triggered Autoimmune Encephalopathies: Interpretation of the Cunningham Panel Results

Dr. Craig D. Shimasaki, PhD, MBA is President & CEO Moleculera Labs, Inc.

PANS and PANDAS are infection-induced autoimmune conditions that disrupt a patient’s normal neurologic functioning. PANS and PANDAS can include a variety of symptoms, such as OCD, motor tics, anxiety, irritability, hyperactivity, sleep disturbances, mood swings, depression, hyperactivity, difficulty concentrating, behavioural regression and urinary problems. This condition can exist in adults too, not just children.

This is the second of three webinars on this topic. In the first webinar Dr. Shimasaki explains the background to the Cunningham Panel and indications for its use. To view the first webinar see below or follow this link https://aonm.org/view-past-webinars/

In this second webinar Dr. Shimasaki will focus on how to interpret the findings, including new study results that substantiate correlations between results and patient symptoms/outcomes.

Moleculera Labs is the only lab in the world to test for autoimmune activity against neuronal targets in the brain that is used by clinics/practitioners across the world to identify encephalitic-type activity called “PANS/PANDAS” in children, and autoimmune encephalopathy in adults. It is characterised by many symptoms that are often considered psychiatric and not given any further biomedical exploration.

Dr. Craig D. Shimasaki

PDF presentation of the webinar

Dr. Shimasaki's presentation

NEURO-AUTOIMMUNE CONDITIONS AND HOW TO TEST FOR THEM

Dr. Craig D. Shimasaki, PhD, MBA is President & CEO Moleculera Labs, Inc.

Moleculera Labs is the only lab in the world to test for autoimmune activity against neuronal targets in the brain that is used by clinics/practitioners across the world to identify encephalitic-type activity called “PANS/PANDAS” in children, and autoimmune encephalopathy in adults. It is characterised by many symptoms that are often considered psychiatric and not given any further biomedical exploration. He will explain the use of the Cunningham Panel, how to interpret the results, and its application in therapy. This will be the first of three webinars on this topic

Dr Shimisaki is a scientist with over 33 years of clinical diagnostic and therapeutic R&D experience, starting his career at Genentech. During his tenure he has been involved in the research, development and clinical testing of neuropsychiatric drugs and diagnostics, genetic testing for predisposition to non-familial breast cancer, a gp-120 HIV vaccine, and influenza and RSV diagnostics and therapeutics. He co-founded Moleculera Labs with Dr. Madeleine Cunningham, an autoimmune neurobiology clinical laboratory based upon her 20+ years of research on infection-triggered autoimmune disorders.

His focus has been to translate basic research discoveries into acutely needed medical products for patients who need them. He has led five clinical diagnostic tests through FDA approval process and is a co-inventor on several medical and diagnostic patents. Dr. Shimasaki is an Adjunct Professor at the University of Oklahoma. He has authored and edited two books “The Business of Bioscience: What Goes Into Making a Biotechnology Product” and “Biotechnology Entrepreneurship: Starting, Managing and Leading Biotech Companies.” He received his BS in Biochemistry from University of California at Davis, his PhD in Molecular Biology from the University of Tulsa, and his MBA from Northwestern University, Kellogg School of Business.

Dr. Armin Schwarzbach

PDF presentation of the webinar

pdf of the presentation slides

IDENTIFYING STEALTH INFECTIONS THAT MAY UNDERLIE ME, FIBROMYALGIA AND OTHER SYNDROMES

Dr. Schwarzbach is Founder and Medical Director at ArminLabs, Augsburg, Germany.

He presented evidence of the different bacterial and viral infections that can lead to syndromes that are often labelled unexplained or psychiatric in nature, and gave insights from his three decades of experience in this field. He explains algorithims for deciding which to test for, and also answered a number of questions in a live Q&A.
Please see https://aonm.org/armin-labs/ for background information on this lab and its tests.

As a Medical Doctor and specialist in laboratory medicine with three decades of experience in clinical medicine and laboratory testing, Dr. Schwarzbach specialises in laboratory medicine in infectiology, microbiology, immunology, hematology, clinical chemistry, endocrinology and gynecological endocrinology.

presentation can be seen at the link below

PDF Presentation

TESTING CIRCULATING CANCER CELLS, CHEMOSENSITIVITY AND THE EFFECTIVENESS OF NATURAL AGENTS

Professor Dr. med. Katharina Pachmann is the founder of the Maintrac system of identifying circulating cancer cells in a “liquid biopsy”, and runs the Maintrac laboratory in Bayreuth, Germany, together with Dr. Ulrich Pachmann and a staff of 45.

Professor Katharina Pachmann explained how the Maintrac test in Germany tests for circulating cancer cells, the circumstances within which it may be appropriate to use it, and how it tests for the effectiveness of chemotherapeutic as well as natural agents. Please see https://aonm.org/maintrac/

As both a medical doctor and research scientist, she has been conducting studies in this field and refining related techniques for over two decades, and has authored over a hundred scientific publications on the technique (https://aonm.org/scientific-articles-and-studies/).

She received her PhD from the Institute for Haematology at the Society for Radiological Research, Munich, and worked as the Head of the Department of Experimental Haematology and Oncology, Friedrich Schiller-University, Jena, for many years. She is a visiting scientist at the University Clinic, Graz, Austria, and has also served in the same capacity at MD Anderson Cancer Center Houston Texas Section of Molecular Hematology and Therapy.

Scroll Up